Abstract
The peptide fragmentof human serum albumin that wasidentifiedas an inhibitor of C-X-C motif chemokine receptor 4(CXCR4), termed EPI-X4, was investigated as a scaffold for the developmentof CXCR4-targeting radio-theragnostics. Derivatives of its truncatedversion JM#21 (ILRWSRKLPCVS) were conjugated to 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraaceticacid (DOTA) and tested in Jurkat and Ghost-CXCR4 cells. Ligand-1, -2, -5, -6, -7, -8, and -9 were selected forradiolabeling. Molecular modeling indicated that Lu-177-DOTAincorporation C-terminally did not interfere with the CXCR4 binding.Lipophilicity, in vitro plasma stability, and cellularuptake hinted Lu-177-7 as superior. In Jurkatxenografts, all radioligands showed >90% washout from the bodywithinan hour, with the exception of Lu-177-7 and Lu-177-9. Lu-177-7 demonstratedbest CXCR4-tumor targeting. Ex vivo biodistributionand single-photon emission computed tomography (SPECT)/positron emissiontomography (PET)/CT imaging of Lu-177-7/Ga-68-7 showed the same distribution profile forboth radioligands, characterized by very low uptake in all nontargetedorgans except the kidneys. The data support the feasibility of CXCR4-targetingwith EPI-X4-based radioligands and designate ligand-7 as a lead candidate for further optimization.
Funding Information
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030L_192476)
  • Deutsche Forschungsgemeinschaft (316249678 SFB 1279, EXC-2033 - 390677874, MU 3115/11-1, MU 3115/8-1)
  • Baden-Württemberg Stiftung
  • Universität Ulm (L.SBN.0209)

This publication has 46 references indexed in Scilit: